OBJECTIVE: To determine the short-term effects of glucosamine (GLN) and chondroitin sulfate (CS) on expression of genes encoding inflammatory mediators and matrix enzymes in bovine cartilage explants stimulated with interleukin 1 (IL-1). METHODS: Dose-response experiments were conducted for IL-1, GLN, and CS to select concentrations of each optimized for detecting treatment effects on cartilage explants. Based on the dose-response experiments, treatments included fetal bovine serum (FBS) control, 15 ng/ml IL-1, and 15 ng/ml IL-1 with the addition of 10 microg/ml GLN and 20 microg/ml CS. Media were measured for nitric oxide (NO) and prostaglandin E2 (PGE2) while explants were frozen for RNA extraction at 8, 16, and 24 hours. Gene expression relative to FBS control for inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), microsomal PGE synthase-1 (mPGEs1), nuclear factor-kB p65 subunit (NF-kB), matrix metalloproteinase (MMP)-3 and 13, aggrecanase (Agg)-1 and 2, and tissue inhibitor of metalloproteinase-3 (TIMP-3) were assessed by quantitative real-time polymerase chain reaction (RT-PCR). In a separate study using incubation of explants with the same treatments for 48 hours, proteoglycan release was measured with dimethylmethylene blue assay and TIMP-3 protein was evaluated with Western blots. RESULTS: The GLN and CS combination abrogated IL-1-induced gene expression of iNOS, COX-2, mPGEs1, and NF-kB at all timepoints. NO, PGE2, and proteoglycan release were reduced with the combination. The abundance of stimulated MMP-13, Agg-1, and Agg-2 mRNA was repressed, whereas TIMP-3 was upregulated by the combination at all timepoints. The abundance of TIMP-3 protein was increased by the combination relative to IL-1 at 48 hours. CONCLUSION: GLN and CS in combination suppress synthesis and expression of genes encoding inflammatory mediators and proteolytic enzymes while upregulating TIMP-3. This provides a plausible mechanism for the purported mild antiinflammatory and chondroprotective properties of GLN and CS.
OBJECTIVE: To determine the short-term effects of glucosamine (GLN) and chondroitin sulfate (CS) on expression of genes encoding inflammatory mediators and matrix enzymes in bovine cartilage explants stimulated with interleukin 1 (IL-1). METHODS: Dose-response experiments were conducted for IL-1, GLN, and CS to select concentrations of each optimized for detecting treatment effects on cartilage explants. Based on the dose-response experiments, treatments included fetal bovine serum (FBS) control, 15 ng/ml IL-1, and 15 ng/ml IL-1 with the addition of 10 microg/ml GLN and 20 microg/ml CS. Media were measured for nitric oxide (NO) and prostaglandin E2 (PGE2) while explants were frozen for RNA extraction at 8, 16, and 24 hours. Gene expression relative to FBS control for inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), microsomal PGE synthase-1 (mPGEs1), nuclear factor-kB p65 subunit (NF-kB), matrix metalloproteinase (MMP)-3 and 13, aggrecanase (Agg)-1 and 2, and tissue inhibitor of metalloproteinase-3 (TIMP-3) were assessed by quantitative real-time polymerase chain reaction (RT-PCR). In a separate study using incubation of explants with the same treatments for 48 hours, proteoglycan release was measured with dimethylmethylene blue assay and TIMP-3 protein was evaluated with Western blots. RESULTS: The GLN and CS combination abrogated IL-1-induced gene expression of iNOS, COX-2, mPGEs1, and NF-kB at all timepoints. NO, PGE2, and proteoglycan release were reduced with the combination. The abundance of stimulated MMP-13, Agg-1, and Agg-2 mRNA was repressed, whereas TIMP-3 was upregulated by the combination at all timepoints. The abundance of TIMP-3 protein was increased by the combination relative to IL-1 at 48 hours. CONCLUSION:GLN and CS in combination suppress synthesis and expression of genes encoding inflammatory mediators and proteolytic enzymes while upregulating TIMP-3. This provides a plausible mechanism for the purported mild antiinflammatory and chondroprotective properties of GLN and CS.
Authors: Griffith A Bell; Elizabeth D Kantor; Johanna W Lampe; Danny D Shen; Emily White Journal: Eur J Epidemiol Date: 2012-07-25 Impact factor: 8.082
Authors: Mario Simental-Mendía; Adriana Sánchez-García; Félix Vilchez-Cavazos; Carlos A Acosta-Olivo; Víctor M Peña-Martínez; Luis E Simental-Mendía Journal: Rheumatol Int Date: 2018-06-11 Impact factor: 2.631
Authors: Vincent P Willard; Brian O Diekman; Johannah Sanchez-Adams; Nicolas Christoforou; Kam W Leong; Farshid Guilak Journal: Arthritis Rheumatol Date: 2014-11 Impact factor: 10.995
Authors: Lloydine Jacobs; Nam Vo; Joao Paulo Coelho; Qing Dong; Bernard Bechara; Barrett Woods; Eric Hempen; Robert Hartman; Harry Preuss; Judith Balk; James Kang; Gwendolyn Sowa Journal: Spine (Phila Pa 1976) Date: 2013-05-20 Impact factor: 3.468
Authors: G Herrero-Beaumont; M E Marcos; O Sánchez-Pernaute; R Granados; L Ortega; E Montell; J Vergés; J Egido; R Largo Journal: Br J Pharmacol Date: 2008-04-21 Impact factor: 8.739
Authors: Jessie A Satia; Alyson Littman; Christopher G Slatore; Joseph A Galanko; Emily White Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-05 Impact factor: 4.254
Authors: Elizabeth D Kantor; Cornelia M Ulrich; Robert W Owen; Peter Schmezer; Marian L Neuhouser; Johanna W Lampe; Ulrike Peters; Danny D Shen; Thomas L Vaughan; Emily White Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-08-05 Impact factor: 4.254